ER-100: Has the First Human Trial of Cellular Rejuvenation Begun?
ER-100 is an experimental gene therapy designed to test whether controlled partial epigenetic reprogramming can restore function in damaged retinal nerve cells. The therapy uses three transcription factors, OCT4, SOX2 and KLF4, collectively called OSK. Earlier animal research reported regeneration of injured optic nerves, more youthful patterns of DNA methylation and gene expression, and improvement in visual function in aged mice and experimental glaucoma.
ER-100 entered a first-in-human Phase 1 trial in 2026 involving people with open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy, or NAION. The therapy is injected into one eye using a modified adeno-associated virus vector, and oral doxycycline is used for 56 days to control OSK expression. The immediate purpose of the study is safety and tolerability, although researchers are also following visual function and retinal structure. No human evidence currently shows that ER-100 reverses biological aging, rejuvenates other organs or extends lifespan.
National Geographic devoted its September 2026 cover story to a question that has moved steadily from speculative longevity discussions into serious laboratory research: can some aspects of cellular aging be reversed rather than merely slowed?
ER-100 is one of the first attempts to test that question directly in humans. The experimental gene therapy uses three cellular reprogramming factors, OCT4, SOX2 and KLF4, to alter patterns of gene activity in damaged retinal nerve cells while attempting to preserve the cells' identity and function.
Earlier mouse research was compelling enough to justify further investigation. OSK expression promoted regeneration of damaged optic-nerve fibers, restored more youthful epigenetic patterns and improved visual function in aged animals and experimental glaucoma. ER-100 has now moved into a small Phase 1 trial involving people with serious optic-nerve disease.
The study is not a trial of human age reversal. Its primary purpose is to determine whether this form of partial epigenetic reprogramming can be delivered safely to the human eye. If researchers eventually show that damaged human retinal neurons can recover meaningful function after controlled reprogramming, it would provide important evidence that at least some age- or injury-related cellular changes may be biologically reversible.
ER-100 and the Question of Cellular Rejuvenation
Longevity research produces no shortage of claims about reversing biological age. ER-100 deserves attention for a different reason: a mechanism that produced unusual results in animal models is now being tested in people.
ER-100 is an experimental gene therapy being studied in optic-nerve diseases. Researchers are not attempting to make study participants younger or extend their lifespan. They are testing whether damaged retinal ganglion cells can be shifted toward a more youthful pattern of gene activity and whether that process can be performed safely.
If those cells eventually show meaningful recovery of function, the finding would have implications beyond ophthalmology. It would not demonstrate that aging itself has been reversed, but it could establish that certain age- or injury-associated changes in mature human neurons are more reversible than previously assumed.
Why Epigenetic Reprogramming Matters
Cells throughout the body contain essentially the same underlying DNA, yet a retinal neuron behaves very differently from a liver cell or muscle cell because different genes are switched on or off. Epigenetic mechanisms help regulate that activity without changing the underlying DNA sequence.
Those regulatory patterns change with development, environment, disease and age. Epigenetic alterations are now recognized as one component of the broader biology of aging.
This is important because aging is not produced by one molecular defect. Genomic instability, mitochondrial dysfunction, cellular senescence, loss of proteostasis, chronic inflammation, altered nutrient sensing and other processes also change over time. HormoneSynergy reviews this broader framework in The Hallmarks of Aging and The Science of Longevity Medicine.
ER-100 is therefore testing one part of aging biology rather than attempting to correct every process associated with aging.
Where the Idea Came From
The scientific foundation for ER-100 traces back in part to cellular reprogramming research associated with Shinya Yamanaka, whose work demonstrated that mature cells could be pushed back toward a pluripotent, stem-cell-like state through the expression of specific transcription factors.
That discovery fundamentally changed the understanding of cellular identity. A mature cell was not necessarily permanently fixed in its existing biological state.
Complete reprogramming, however, is not what researchers want from a retinal neuron. A functioning retinal ganglion cell must remain a retinal ganglion cell. Reprogramming it too extensively could erase the cellular identity and specialized function that treatment is supposed to preserve.
Partial epigenetic reprogramming takes a more limited approach. The goal is to restore selected youthful patterns of gene activity without returning the cell to a pluripotent state.
ER-100 uses three transcription factors associated with the Yamanaka-factor system: OCT4, SOX2 and KLF4, collectively known as OSK.
What the 2020 Mouse Research Actually Showed
Much of the scientific interest comes from a 2020 study published in Nature by Yuancheng Lu and colleagues.
The researchers expressed OSK in retinal ganglion cells, the neurons that carry visual information from the retina through the optic nerve toward the brain. In mice, OSK expression promoted optic-nerve axon regeneration following injury and was associated with restoration of more youthful patterns of DNA methylation and gene expression.
The investigators also reported improvement in visual function in aged mice and in a mouse model of glaucoma.
These findings were particularly interesting because mature central nervous system neurons have limited regenerative capacity. The study suggested that older mammalian cells may retain biological information capable of supporting a more youthful pattern of function when the appropriate regulatory pathways are altered.
The work did not establish that aging had been reversed throughout the animal. It showed that manipulating epigenetic regulation in a specific cell population could influence regeneration, gene expression, methylation patterns and function.
Read the original 2020 Nature study.
How ER-100 Actually Works
The current human trial provides more detail about how the experimental therapy is being delivered and controlled.
ER-100 uses a modified adeno-associated virus, or AAV, vector to deliver genetic instructions for producing OCT4, SOX2 and KLF4 to retinal cells. The treatment is given as a single intravitreal injection into one eye.
The vector does not replace or edit the participant's existing genes. Instead, it delivers instructions that allow targeted cells to produce the OSK transcription factors.
Expression is controlled with doxycycline. Participants take systemic doxycycline for eight weeks, or 56 days, to activate OSK expression. This provides investigators with a way to control when the reprogramming factors are active rather than leaving them continuously expressed.
The modified AAV vector has also been engineered so that it cannot cause an infectious viral illness.
This combination of local ocular delivery and controlled OSK expression is central to the design of the first human study.
Why Start With the Eye?
The eye offers several practical advantages for a first human trial of partial epigenetic reprogramming.
A therapy can be delivered directly into one eye rather than systemically throughout the body. Retinal structures can be examined repeatedly using high-resolution imaging. Researchers can measure vision objectively, and the untreated eye may provide useful clinical context for some assessments.
The target diseases also involve retinal ganglion cells, the same general neuronal population studied extensively in the earlier animal work.
Open-angle glaucoma causes progressive damage to retinal ganglion cells and the optic nerve. Treatments can reduce intraocular pressure and slow disease progression, but they do not ordinarily regenerate neurons that have already been lost.
NAION results from acute ischemic injury to the optic nerve and can cause sudden, permanent visual loss. There is currently no established treatment capable of restoring the damaged retinal ganglion cells.
These conditions therefore provide a clinically meaningful setting in which to ask whether partial reprogramming can influence damaged human neurons.
ER-100 Has Now Reached Humans
Life Biosciences announced in January 2026 that the FDA had cleared its Investigational New Drug application for ER-100, allowing the therapy to enter clinical testing. IND clearance permits a clinical trial to proceed. It is not FDA approval of the treatment.
The Phase 1 trial, NCT07290244, began on March 2, 2026 and is currently listed as recruiting. Up to 18 participants are planned: as many as 12 with open-angle glaucoma and six with NAION.
The glaucoma portion begins with dose escalation. Participants receive ER-100 in one eye, with independent safety review before enrollment proceeds at each dose level. The NAION cohort follows after a dose is selected using the safety and tolerability information obtained in the glaucoma group.
Life Biosciences publicly announced the first participant dosing on June 9, 2026.
View the current ER-100 Phase 1 trial record at ClinicalTrials.gov.
What Researchers Are Watching for in the Phase 1 Trial
The trial is primarily a safety and tolerability study. That distinction matters when discussing an experimental therapy this early in development.
Researchers are monitoring treatment-emergent adverse events and dose-limiting toxicities during and after the period of doxycycline-controlled OSK expression. The protocol also includes detailed eye examinations and retinal imaging.
Investigators are evaluating immune responses to the AAV vector, including neutralizing antibodies. They are also testing tears, saliva, blood, urine, feces and other samples for evidence of vector shedding and studying where vector DNA can be detected.
Visual outcomes are being measured as well, which may provide early information about biological activity. Phase 1 trials of this size, however, are not designed to establish definitive efficacy.
Participants are scheduled for long-term follow-up extending as far as five years. ClinicalTrials.gov currently lists estimated primary completion in May 2027 and estimated study completion in March 2032.
Does ER-100 Mean Human Aging Can Be Reversed?
No human evidence currently supports that conclusion.
There is a substantial biological difference between altering epigenetic regulation in a localized population of retinal neurons and rejuvenating the human body.
The eye allows researchers to place therapy directly into a defined anatomical space. Whole-body reprogramming would require control over which tissues receive treatment, which cells express the reprogramming factors, how strongly those factors are expressed, how long they remain active and how different tissues respond.
Aging is also broader than the epigenome. DNA damage, mitochondrial dysfunction, cellular senescence, protein quality control, stem-cell function, immune aging, inflammation and changes in intercellular communication all contribute to age-related decline.
Some of these processes may interact with epigenetic regulation. It remains unknown whether partial reprogramming can beneficially influence them in humans or whether the approach can eventually be extended safely beyond specific tissues.
The complexity is illustrated from another direction by our review of a woman who lived to 117. Her biology contained clear evidence of extreme aging alongside unusually resilient metabolic, inflammatory and epigenetic features. See She Lived to 117—and Her Body Still Aged.
What Would Constitute an Important Human Result?
The first meaningful evidence does not need to involve lifespan or whole-body rejuvenation.
If ER-100 can eventually be shown to restore measurable function in damaged human retinal neurons through controlled partial reprogramming, that would be an important regenerative-medicine finding on its own.
Medicine has historically managed many forms of age-related degeneration by preserving remaining function, reducing risk or slowing further decline. Regenerative medicine raises a different possibility: whether cells that have already lost function can recover some of it.
The Phase 1 study will not settle that question definitively. Its primary role is to determine whether the intervention can be delivered with an acceptable safety profile and to identify signals that justify larger clinical trials.
Animal Rejuvenation and Human Rejuvenation Are Not the Same Claim
Longevity research frequently moves through a predictable sequence. A biological mechanism produces a striking result in cells or animals, public interest grows rapidly, and conclusions begin to outrun the human evidence.
ER-100 is at the stage where restraint is especially important.
The underlying biology is legitimate. The 2020 animal work was published in a major peer-reviewed journal. The therapy has progressed through preclinical development and into a regulated human trial. None of that establishes that ER-100 works in humans.
It has not yet been demonstrated that ER-100 restores vision in people, reverses the biological age of human retinal cells in a clinically meaningful way, rejuvenates the brain or other organs, or extends human healthspan or lifespan.
The scientific importance of the study is that those assumptions are no longer being discussed only in animal models. A controlled form of partial epigenetic reprogramming is now being tested in living human tissue.
The HormoneSynergy® Perspective
ER-100 sits in an unusual place within longevity research. The concept is ambitious, the preclinical findings are substantial enough to take seriously, and the human evidence is still at its beginning.
That combination calls for neither dismissal nor exaggerated expectation.
For now, ER-100 should be understood as an experimental treatment for serious optic neuropathies and an early human test of controlled partial epigenetic reprogramming. The first questions are safety, tolerability and whether there is credible evidence of biological or visual benefit.
If those questions are answered favorably, research can move on to larger trials and eventually to the much more difficult questions surrounding other tissues and age-related diseases.
Until those data exist, claims that human aging has been reversed remain ahead of the evidence.
Readers interested in the larger biology can explore The Science of Longevity Medicine, The Hallmarks of Aging, or the HormoneSynergy® Longevity Medicine Resource Library.
Frequently Asked Questions
What is ER-100?
ER-100 is an investigational AAV-based gene therapy designed to produce controlled expression of three transcription factors, OCT4, SOX2 and KLF4, in retinal cells. The approach is intended to test whether partial epigenetic reprogramming can restore function in cells damaged by age or disease.
Is ER-100 FDA approved?
No. The FDA cleared an Investigational New Drug application allowing ER-100 to enter human clinical testing. IND clearance permits a clinical trial to proceed but does not mean the treatment has been approved as safe or effective. ER-100 remains investigational.
Does ER-100 change a person's genes?
The current clinical-trial description states that ER-100 does not alter the participant's existing genes. A modified AAV vector delivers genetic instructions that allow retinal cells to produce the OSK transcription factors during the controlled treatment period.
Why do participants take doxycycline with ER-100?
Doxycycline is used as part of the system that controls OSK expression. Participants take systemic doxycycline for eight weeks, or 56 days, after ER-100 administration to activate expression of the reprogramming factors.
Does ER-100 reverse aging?
Human age reversal has not been demonstrated. Animal research suggests that OSK reprogramming can restore more youthful epigenetic patterns and improve retinal function in certain experimental settings. The current human trial is primarily designed to establish safety and tolerability.
What are OSK and the Yamanaka factors?
OSK refers to OCT4, SOX2 and KLF4, three transcription factors involved in cellular reprogramming. They are three of the four factors used in Shinya Yamanaka's landmark work showing that mature cells can be reprogrammed toward a pluripotent state. ER-100 uses a controlled partial-reprogramming strategy rather than attempting to erase the cell's mature identity.
Why is ER-100 being tested in the eye?
The eye allows researchers to administer the therapy locally, examine retinal structures in detail and measure visual function objectively. Open-angle glaucoma and NAION also damage retinal ganglion cells, making them clinically relevant conditions for testing whether partial reprogramming can influence injured neurons.
How many people are in the ER-100 trial?
The Phase 1 study plans to enroll up to 18 participants, including as many as 12 people with open-angle glaucoma and six with NAION.
When will we know whether ER-100 works?
ClinicalTrials.gov currently lists estimated primary completion in May 2027, with long-term follow-up extending through approximately March 2032. Phase 1 may provide early visual or biological signals, but determining whether ER-100 is effective will likely require larger controlled clinical trials.
Could partial epigenetic reprogramming eventually be used in the brain, muscles or other organs?
Researchers are investigating partial reprogramming in several tissues and disease models, but safe rejuvenation of major human organs or the entire body has not been demonstrated. Delivery, cell targeting, dosing, immune response, duration of expression and preservation of cellular identity remain major challenges.
Related HormoneSynergy® Reading
- The Science of Longevity Medicine
- The Hallmarks of Aging Explained
- She Lived to 117—and Her Body Still Aged
- HormoneSynergy® Longevity Medicine Resource Library
Editorial Transparency
Published August 2026. Updated September 14, 2026. ER-100 is an investigational therapy undergoing Phase 1 human testing and is not FDA approved for glaucoma, NAION, aging or any anti-aging indication. HormoneSynergy® has no financial relationship with Life Biosciences or ER-100. This article is educational commentary on emerging longevity and regenerative-medicine research. Company statements are identified as such, and conclusions about safety or efficacy will require human clinical data.
Sources
ClinicalTrials.gov. Phase 1 Study of ER-100 in Open-Angle Glaucoma and NAION. NCT07290244.
National Geographic. Are We on the Brink of Ending Aging? 2026.
Get the HormoneSynergy® Longevity Letter for new evidence-based articles, clinical updates and practical information about longevity and preventive health.
Sign up for the HormoneSynergy® Longevity Letter
This article is part of the HormoneSynergy® Longevity Medicine education series covering preventive cardiology, metabolic health, hormone optimization, body composition, and advanced diagnostics for healthy aging.
Return to the Longevity Medicine Guide →